Treatment of RF-Positive RA with Multiple Drug Intolerances

Introduction to Treatment Options

• The European League Against Rheumatism (EULAR) recommends TNF inhibitors as first-line biologics when MTX/DMARD therapy fails, with a preference for combination therapy with a conventional DMARD like leflunomide or sulfasalazine 1, 5, 7
• For patients who cannot tolerate MTX, leflunomide is the preferred first alternative, with sulfasalazine being equally recommended as a first-line MTX alternative 2, 3, 1

Biologic Treatment Options

• TNF inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab) combined with leflunomide or sulfasalazine are recommended for patients who have failed MTX and other DMARDs 1, 2
• Non-TNF biologics such as abatacept, rituximab, or returning to a previously effective biologic like Actemra (tocilizumab) can be considered if TNF inhibitors fail or are contraindicated 1, 5, 4

Treatment Monitoring and Adjustment

• Disease activity should be assessed every 1-3 months during active disease, with adjustments to therapy made if no improvement is seen by 3 months or if treatment targets are not reached by 6 months 1, 8, 2

Glucocorticoid Use

• Low-dose glucocorticoids (≤10 mg/day prednisone equivalent) can be added when starting a new regimen, with tapering as rapidly as clinically feasible, ideally within 3-6 months 2, 1

Insurance Coverage and Special Considerations

• For RF-positive patients, rituximab may be a particularly good option if TNF inhibitors fail, due to its efficacy in this patient population 4
• When seeking insurance coverage, it is essential to document MTX intolerance, failure of other treatments, and the presence of poor prognostic factors such as RF-positive disease 1, 8, 4